2015 American Society of Hematology Annual Meeting*

December 5-8, 2015; Orlando, Florida
John Burke, MD, and Brad S. Kahl, MD, review data from key studies in non-Hodgkin’s lymphomas, chronic lymphocytic leukemia, small lymphocytic lymphoma, and Hodgkin’s lymphoma presented at the 2015 American Society of Hematology Annual Meeting.
John M. Burke, MD
Brad S. Kahl, MD


DA-EPOCH-R highly active in Burkitt lymphoma with reduced toxicity vs high-intensity treatment regimens.

Released: December 11, 2015

Fewer AEs and significantly longer PFS and ORR with ibrutinib vs temsirolimus.

Released: December 9, 2015

Phase II data suggest that the chemotherapy-free regimen of ibrutinib plus rituximab is highly active in treatment-naive FL.

Released: December 10, 2015

Ibrutinib is active in primary CNS lymphoma, achieving clinically meaningful CSF concentrations.

Released: December 8, 2015

In this phase III trial that enrolled elderly treatment-naive patients with CLL, ibrutinib was associated with significant reductions in risk of progression and death vs chlorambucil.

Released: December 12, 2015

In this phase II trial, R-bendamustine induction showed similar response rates, 2-year PFS, and 2-year OS with less hematologic and marrow toxicity vs R-hyperCVAD.

Released: December 11, 2015

Use of interim PET allows more patients to avoid IFRT while still achieving 3-year PFS.

Released: December 12, 2015

Phase I/II data suggest promise of combining brentuximab vedotin with ESHAP for patients with relapsed/refractory cHL who are transplantation candidates.

Released: December 15, 2015

In this early study, pembrolizumab was highly active with durable responses in heavily pretreated patients with cHL who had failed brentuximab vedotin.

Released: December 14, 2015

Alternate kinase inhibitor therapy following ibrutinib or idelalisib discontinuation can be efficacious.

Released: December 12, 2015

Addition of 2 doses of bortezomib to frontline R-CHOP resulted in similar 2-year PFS rates in non-GCB DLBCL defined by the Hans IHC method.

Released: December 12, 2015

Preliminary data show promising activity for the combination of venetoclax and rituximab, including an ORR of 86% and durable responses in the 55% of patients who achieved MRD negativity.

Released: December 16, 2015

In this early-stage study, ACP-196 demonstrated promising activity in high-risk R/R CLL regardless of the presence of del(17p).

Released: December 15, 2015

In this expert analysis, John M. Burke, MD, and Brad S. Kahl, MD, discuss the most clinically relevant data on the management of lymphomas presented at the 2015 American Society of Hematology annual meeting.

John M. Burke, MD Brad S. Kahl, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 17, 2016 Expiration: February 16, 2017

Combination idelalisib plus BR therapy significantly improved survival outcomes in patients with R/R CLL.

Released: December 17, 2015

Single-agent venetoclax is active and achieved deep responses in relapsed/refractory CLL with del(17p).

Released: December 14, 2015

In this downloadable slideset, John M. Burke, MD, and Brad S. Kahl, MD, review data from key studies in lymphoma presented at the 2015 American Society of Hematology Annual Meeting.

Released: January 25, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?